Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 2,292	$ 571	$ 5,293	$ 2,473
General and administrative	1,601	2,533	4,926	6,725
Total operating expenses	3,893	3,104	10,219	9,198
Loss from operations	(3,893)	(3,104)	(10,219)	(9,198)
Other income (expense):
Change in fair value of warrant liabilities	(87)		2,901
Interest income	162		162
Other expense		(9)		(93)
Loss before income taxes	(3,818)	(3,113)	(7,156)	(9,291)
Provision for income taxes	0	0	0	0
Net loss	(3,818)	(3,113)	(7,156)	(9,291)
Other comprehensive loss, net of tax				(4)
Comprehensive loss	$ (3,818)	$ (3,113)	$ (7,156)	$ (9,295)
Loss per share:
Net loss per share, basic	$ (0.09)	$ (3.50)	$ (0.18)	$ (10.45)
Net loss per share, diluted	$ (0.09)	$ (3.50)	$ (0.18)	$ (10.45)
Weighted average shares of common stock outstanding:
Basic (in shares)	40,606,537	888,693	40,517,356	888,693
Diluted (in shares)	40,606,537	888,693	40,517,356	888,693